Reality of Trump’s drug pricing to set in over next 18 months
Novartis‘ CEO warned Tuesday that the U.S. drug pricing policy under President Donald Trump poses a “very difficult situation” and the reality will soon catch up with both drugmakers and patients. “The longer-term implications are significant,” CEO Vas Narasimhan told CNBC’s Carolin Roth. “The reality of MFN is going to set in in the next…